Weekly Journal Scan: Extending anticoagulation beyond 6 months after venous thromboembolism in patients with active cancer. Is low-dose apixaban the answer?

European Heart Journal

27 May 2025

Organised by:

Read full article

Contributors

Mattia Galli

Mattia Galli

Author

Carlo Patrono

Carlo Patrono

Author

You may be interested in

Congress Presentation

Comparative effectiveness and safety of apixaban and low-molecular weight heparin among patients with venous thromboembolism and active cancer in an extended treatment setting

28 August 2023

Webinar

Cardiac monitoring after ischaemic stroke: evidence and clinical practice

14 June 2021

Congress Presentation

Low-dose anticoagulation for peripheral deep vein thrombosis of the lower extremities in cancer patients

27 August 2022

Congress Session

Don’t forget to look right

18 May 2025

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources